Sihuan Pharmaceutical's (HKG:0460) new drug application for the new indication of Anaprazole Sodium Enteric-coated Tablets was accepted by China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.
The acceptance is for the drug, developed by Xuanzhu Biopharmaceutical, a unit of the company, to treat adult reflux esophagitis.